Psychiatr. pro Praxi, 2006; 5: 214-224

The Pharmacotherapy of Depression

doc. MUDr. Ján Praško CSc1,3,2,4, MUDr. Hana Prašková1
1 Psychiatrické centrum Praha, 3. LF UK, Praha
2 Centrum neuropsychiatrických studií, Praha
3 Psychiatrická klinika FN a LF UP, Olomouc
4 3. LF UK, Praha

The introduction of antidepressants revolutionized not only the treatment of depression but also the way we view the disease itself. In this article, we discuss the treatment of depression, with a focus on proper evaluation, choice of an agent and strategies in the case of resistance to the treatment.

Keywords: depression, antidepressants, psychiatric evaluation, medical evaluation, comorbidity, drug-drug interaction, side effects, specific populations, acute treatment period, continuation period, maintenance period

Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Praško J, Prašková H. The Pharmacotherapy of Depression. Psychiatr. praxi. 2006;7(5):214-224.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Agosti V a Ocepek-Welikson K. The efficacy of imipramine and psychotherapy in early-onset chronic depression: a reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Affect Disord 1997; 43: 181-186. Go to original source... Go to PubMed...
    2. Altamura AC, DeNovellis F, Guercetti G et al. Fluoxetine compared with amitriptylin in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989; 9: 391-396.
    3. Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617-1622. Go to original source... Go to PubMed...
    4. American Academy of Child and Adolescent Psychiatry: Practice parameters for the assessment and treatment of children and adolescents with depressive disorder. J Am Acad Child Adolescence Psychiatry 1998; 37(suppl): 63S-83S. Go to original source... Go to PubMed...
    5. American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(Suppl.): 1-45.
    6. American Psychiatric Association: Practice Guidelines for the Treatment of Psychiatric Disorders, Compendium 2002. American Psychiatric Association, United States of America, Washington, D.C., 2002: 463-547.
    7. Anderson IM. SSRIs versus tricyclic antidepressant in depressed inpatients: a meta - analysis of efficacy and tolerability. Depress Anxiety 1998; 7(Suppl. 1): 11-17. Go to original source... Go to PubMed...
    8. Anderson IM. Selective reuptake inhibitors versus tricyclic antidepressants: a meta - analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36. Go to original source... Go to PubMed...
    9. Anderson IM. Meta-analytical studies on new antidepressants. British Medical Bulletin 2001; 57: 161-178. Go to original source... Go to PubMed...
    10. Anghelescu I, Klawe C, Benkert O: Orlistat in the treatment of psychopharmacologically induced weight gain (letter). J Clin Psychopharmacol 2000; 20: 716-717. Go to original source... Go to PubMed...
    11. Appelberg BG, Syvalahti EK, Koskinen TE, Mehtonen OP, Muhonen TT, Naukarinen HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: Results from a placebo-controlled, randomized, double blind, placebo washin study. J Clin Psychiatry 2001; 62: 448-452. Go to original source... Go to PubMed...
    12. Appleby L, Warner R, Whitton A, Faragher B. A controlled study of fluoxetine and cognitivebehavioral counseling in the treatment of postnatal depression. Br Med J 1997; 314: 932-936. Go to original source... Go to PubMed...
    13. Aronson R., Offman HJ, Joffe RT, Naylor CD. Triiodthyronine augmentation in the treatment of refractory depression: a meta - analysis. Arch Gen Psychiatry 1996; 53: 842-848. Go to original source... Go to PubMed...
    14. Austin MPV, Souza FGM, Goodwin GM. Lithium augmentation in antidepressant - resistant patients: a quantitative analysis. Br J Psychiatry 1991; 159: 510-514. Go to original source... Go to PubMed...
    15. Bakish D. New standard of depression treatment: remission and full recovery. JClin psychiatry 2001; 62 (Suppl.2): 5-9.
    16. Ballenger JC. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry 1988; 49(Suppl. 4): 83-88.
    17. Balon R: Case report 5: suicidal ideation during treatment with sertraline. Journal of Drug Development 1993; 6: 77-78.
    18. Barbee JG., Jamhour NJ. Lamotrigine as an augmentation agent in treatment - resistant depression. J Clin Psychiatry 2002; 63: 737-741. Go to original source... Go to PubMed...
    19. Barbui C, Hotopf M. Amitriptyline vs. the rest: Still leading antidepressant after 40 years of randomized clinical trials. Br J Psychiatr 2001; 178: 129-144. Go to original source... Go to PubMed...
    20. Bareš M a Praško J: Depresivní porucha. In: Seifertová D, Praško J, Hőschl C (eds): Postupy v léčbě psychických poruch. Amepra, Praha 2004.
    21. Bauer M, Bschor T, Dieter Kuntz, Berhöfer A, Stöhle A, Müller - Oerlinghausen B. Double blind, placebo controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157: 1429-1435. Go to original source... Go to PubMed...
    22. Bauer M, Dopfmer S. Lithium augmentation in treatment resistant depression: meta-analysis of placebo controlled studies. J Clin Psychopharmacol 1999; 19: 427-434. Go to original source... Go to PubMed...
    23. Bauer M, Helmchen H. General principles of the treatment of depressive and manic disorders. In: Helmchen H, Henn F, Lauter H, Sartorius N (eds) Contemporary Psychiatry. Vol. 3. Springer 2000, Heidelberg, pp.305-316.
    24. Baumann P, Nil R, Souche A, Montaldi S, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier - Perey M. A double - blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy - resistant depressive patient: a clinical, pharmacokinetic and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-314. Go to original source... Go to PubMed...
    25. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD. Meta-analysis of randomized controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the shortterm treatment of major depression. Br J Psychiatry 2000; 176: 421-428. Go to original source... Go to PubMed...
    26. Blackburn IM, Moore RG. Controlled acute and follow - up trial of cognitive therapy and pharmacotherapy in out - patients with recurrent depression. Br J Psychiatry 1997; 171: 328-334. Go to original source... Go to PubMed...
    27. Boland RJ a Keller MB: Treatment of depression. In: Schatzberg AF and Nemeroff CB: Textbook of Psychopharmacology. American Psychiatric Publishing Inc. Washington DC, London, England 2004: 847-864.
    28. Calabrese JR, Bowden CL Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88. Go to original source... Go to PubMed...
    29. The Canadian Journal of Psychiatry, Supplement I (Clinical Practice Guidelines): Clinical Guidelines for The Treatment of Depressive Disorders, June 2001, vol. 46, 91 pages. Go to original source... Go to PubMed...
    30. Carpenter LL, Yasmin SPLH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51: 183-188. Go to original source... Go to PubMed...
    31. Cheer SM a Goa KL: Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61: 81-110. Go to original source... Go to PubMed...
    32. Clayton PF, Grove WM, Coryell W et al.: Follow up and family study of anxious depression. Am J Psychiatry 1991; 148: 1512-1517. Go to original source... Go to PubMed...
    33. Cohn CK, Shrivastava R, Mendels J et al.: Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 (suppl B): 28-33.
    34. Compton SN, Grant PJ, Chrisman et al.: Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 564-571. Go to original source... Go to PubMed...
    35. Cookson J: Side-effects of antidepressants. Br J Psychiatry 1993; 163 (suppl): 20-24. Go to original source...
    36. Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, De Battista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME. The Texas Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 142-156. Go to original source... Go to PubMed...
    37. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GNM, Kramer GL, Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996; 32: 647-652. Go to PubMed...
    38. Devane CL, Laizure SC, Stewart JT et al.: Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990; 10: 328-332. Go to original source... Go to PubMed...
    39. Doyle GD, Laher M, Kelly JG et al.: The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand 1989; 350 (suppl): 89-90. Go to original source... Go to PubMed...
    40. Dubovsky SL, Buzan R. Mood disorder. In: Hales RE, Yudofsky SC, eds. Essentials of clinical psychiatry. Based on The American Psychiatric Press Textbook of psychiatry 3rd ed. Washington: American Psychiatric Press Inc., 1999; 277-344.
    41. Dunner DL, Cohn JB, Walshe T et al. Two combined multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53 (suppl): 57-60.
    42. Einarson A, Fatoye B, Sarkar M et al.: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158: 1728-1730. Go to original source... Go to PubMed...
    43. Emslie GJ, Rush AJ, Weinberg WA et al.: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-1037. Go to original source... Go to PubMed...
    44. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000; 61 (Suppl.1): 26-32.
    45. Fava GA, Grandi S, Zielezny M, Canestari R, Morphy MA. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994; 151: 1295-1299. Go to original source... Go to PubMed...
    46. Fava GA, Rafanelli C., Grandi S, Conti S, Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry 1998; 55: 816-820. Go to original source... Go to PubMed...
    47. Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol 2003; 23: 365-369. Go to original source... Go to PubMed...
    48. Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P. Switching to bupropion in fluoxetine - resistant major depressive disorder. Ann Clin Psychiatry 2003; 15: 17-22. Go to original source...
    49. Fornaro P, Giberti F, Albano C, Cultrera S, Lunardi G. Lamotrigine in the treatment of major depression. Preliminary results from an open study on outpatients. Ital J Psychiatry Behav Sci 1998; 8: 114-118.
    50. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093-1999. Go to original source... Go to PubMed...
    51. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disorder 1993; 27: 139-145. Go to original source... Go to PubMed...
    52. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissmann MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch Gen Psychiatry 1991; 48: 851-855. Go to original source... Go to PubMed...
    53. Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev 2002;1:CD001026. Go to original source...
    54. Geddes JR, McCarney SM, Davies C, Furukawa TA, Kupfer DJ, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorder: a systematic review. Lancet 2003; 361: 653-661. Go to original source... Go to PubMed...
    55. Glassman AH, O´Connor CM, Callif RM, Swedberg K, Schwarz P, Digger JT, Krishnan KKR, Van-Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Madekian J, Harrison WM. Sertraline treatment of major depression in patiens with acute MI or unstable angina. JAMA 2002; 288: 701-709. Go to original source... Go to PubMed...
    56. Guelfi JD, Ansseau M, Timmerman L et al.: Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21: 425-431. Go to original source... Go to PubMed...
    57. Guillibert E, Pelicier Y, Archambault JC: A double-blind multicenter study of paroxetine vs. clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989; 80 (suppl 350) 132-134. Go to original source... Go to PubMed...
    58. Hirschfeld RMA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994; 55(Suppl.): 61-69.
    59. Hirschfeld RMA. Efficacy of SSRI´s and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999; 60: 326-335. Go to original source... Go to PubMed...
    60. Hyperuricum Depression Trial Study Group. Effect of Hyperuricum perforatum (St. John´s Wort) in major depressive disorder. JAMA 2002; 287: 1807-1814. Go to original source... Go to PubMed...
    61. Janicak PG, Davis JM, Preskorn SH et al.: Principles and Practice of Psychopharmacotherapy. Baltimore, MD, Williams & Wilkins1993; 499 p.
    62. Kapur S, Mieczkowski T, Mann JJ: Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 1992; 268: 3441-3445. Go to original source...
    63. Kennedy SH, McCann M, Masellis M, McIntyre RS, Raskin J, McKay G, Baker GB. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63: 181-186. Go to original source... Go to PubMed...
    64. Keller MB, Shapiro RW, Lavori PW et al.: Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatr 1982; 39: 911-915. Go to original source... Go to PubMed...
    65. Keller MB, Lavori PW, Rice J et al.: The persistent risk of chronicity in recurrent episodes of non-bipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 1984; 143: 911-915.
    66. Keller MB, Kocsis JH, Thase ME et al.: Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280: 1665-1672. Go to original source... Go to PubMed...
    67. Keller MB, McCullough JP, Klein D et al: A comparison of nefazodone, the cognitive-behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342: 1462-1470. Go to original source... Go to PubMed...
    68. Keller MB, Ryan ND, Strober M et al.: Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatr 2001; 40: 762-772. Go to original source... Go to PubMed...
    69. Kielholz P, Tarzani S, Gastpar M, Adams C. Zur behandlung therapieresistenter depressionen. Ergebnisse einer kombinierten infusionstherapie. Schweiz Med Wochenschr 1982; 112: 1090-1095. Go to PubMed...
    70. Klerman GL, DiMascio A, Weissman M, Prusoff B, Paykel ES. Treatment of depression by drugs and psychotherapy. Am J Psychiatry 1974; 131: 186-191. Go to original source... Go to PubMed...
    71. Kornstein SG, Schatzberg AF, Thase ME et al.: Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445-1452. Go to original source... Go to PubMed...
    72. Kulin NA, Pastuszak A, Sage SR et al.: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-610. Go to original source... Go to PubMed...
    73. Lam RW, Wan DDC, Cohen NL, Kennedy SH. Combining antidepressants for treatment - resistant depression: a review. J Clin Psychiatry 2002; 63: 685-693. Go to original source... Go to PubMed...
    74. Landen M, Bjorling G, Agren H, Fahlen T. A randomized double blind, placebo - controlled trial of buspirone with an SSRI in patients with treatment resistant depression. J Clin Psychiatry 1998; 59: 664-668. Go to original source... Go to PubMed...
    75. Leon AC, Keller MB, Warshaw MG et al.: Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 1999; 156: 195-201. Go to original source... Go to PubMed...
    76. Lester BM, Cucca J, Andreozzi L et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993; 32: 1253-1255. Go to original source... Go to PubMed...
    77. Levenson J a Fallon H: Fluoxetine treatment of depression caused by interferon-?. Am J Gastroenterol 1993; 88: 760-761.
    78. Licht RW, Quitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomized study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 2002; 161: 143-151. Go to original source... Go to PubMed...
    79. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta - analysis of randomized clinical trials. BMJ 1996; 313: 253-258. Go to original source... Go to PubMed...
    80. Lotufo - Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999; 20: 226-247. Go to original source... Go to PubMed...
    81. Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctot KL, Liu BA, Shulman KI, Silver IL, Narango CA, Shear NH. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Dis 1997; 46: 191-217. Go to original source... Go to PubMed...
    82. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. Selective serotonin reuptake inhibitors. Meta - analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9: 47-52. Go to original source... Go to PubMed...
    83. Mueller TI, Lavori PW, Keller MB et al.: Prognostic effect of the variable course of alcoholism on the 10-year course of depression. Am J Psychiatry 1994; 151: 7701-706. Go to original source...
    84. Muller - Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetz el H, Benkert O. Risperidone versus haloperidol and amitriptyline with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18: 111-120. Go to original source... Go to PubMed...
    85. Nelson JC, Mazure C, Bowers MB. Synergistic effects of fluoxetine and desipramine: a prospective study. 21st meeting of the CINP Congress 1998; Glasgow, Scotland.
    86. NICE. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: National Institute for Clinical Excellence, 2004.
    87. Noyes R Jr, Garvey MJ, Cook BL, Perry PJ. Benzodiazepine withdrawal: a review of evidence. J Clin Psychiatry 1988; 49: 382-389.
    88. Nurnberg HG, Gelenberg A, Hargreave TB et al.: Efficacy of sildenafilu citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. Am J Psychiatry 2001; 158: 1926-1928. Go to original source... Go to PubMed...
    89. Oke A, Adhiyaman V, Aziz K et al.: Dose-dependent seizure activity associated with fluoxetine therapy. QJM 2001; 94: 113-114. Go to original source... Go to PubMed...
    90. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256-259. Go to original source... Go to PubMed...
    91. Parker G: Classifying depression: should paradigms lost be regained? Am J Psychiatry 2000; 157: 1195-1203. Go to original source... Go to PubMed...
    92. Pastuszak A, Schick-Boschetto B, Zuber C et al.: Pregnancy outcome following first trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-2248. Go to original source...
    93. Paykel ES, Scott J, Teasdale JD, Johnson AL, Garland A, Moore R, Jenaway A, Cornwall PL, Hayhurst H, Abbott R, Pope M. Prevention of relapse in residual depression by cognitive therapy. A controlled trial. Arch Gen Psychiatry 1999; 56: 829-835. Go to original source... Go to PubMed...
    94. Praško J, Ondráčková I, Johanovská E, Šípek J, Klár I, Klaschka J, Pěč O, Prašková H: Socioterapie a farmakoterapie v léčbě rekurentních depresí. Závěrečná zpráva o řešení grantu Interní grantové agentury Ministerstva zdravotnictví České republiky, č. projektu 0295-5, 1996; 41 s. + přílohy.
    95. Price LH, Charney DS, Heninger G. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986; 143: 1387-1392. Go to original source... Go to PubMed...
    96. Quitkin FM, McGrath JP, Stewart JW. Chronological milestones to guide drug change: when should clinician switch antidepressant? Arch Gen Psychiatry 1996; 53: 785-792. Go to original source... Go to PubMed...
    97. Raboch J a Anders M: Vodítka pro léčbu depresivních poruch dospělých. Galen 2006, in press.
    98. Reynolds CF: Treatment of depression in special populations. J Clin Psychiatry 1992; 53 (9 suppl): 45-53.
    99. Reynolds III CF, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, Mazumdar S, Houck PR, Stack JA, Pollock BG, Kupfer DJ. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression. A randomized controlled trial in patients older than 59 years. JAMA 1999; 281: 39-45. Go to original source... Go to PubMed...
    100. Riddle MA, Geller B, and Ryan N: Another sudden death in a child treated with desipramin. J Am Acad Child Adolesc Psychiatry 1993; 32: 792-797. Go to original source... Go to PubMed...
    101. Riddle MA, Reeve EA, Yaryura-Tobias JA et al.: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 222-229. Go to original source... Go to PubMed...
    102. Roose SP a Glassman AH: Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J Clin Psychiatry 1989; 7 (2, monogr): 1-18.
    103. Roose SP, Dalack GW, Glassman AH, et al.: Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148: 512-516. Go to original source... Go to PubMed...
    104. Roose SP, Glassman AH, Attia E, et al.: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155: 660-665. Go to original source... Go to PubMed...
    105. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993; 54: 338-342.
    106. Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry 2003; 64: 390-396. Go to original source... Go to PubMed...
    107. Rush AJ. Strategies and tactics in the management of maintenance treatment for depressed patients. J Clin Psychiatry 1999; 60(Suppl.14): 21-26.
    108. Rush AJ. Mood disorders: The treatment of depression. In. Sadock BJ, Sadock VA, eds. Kaplan´s and Sadock´s Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2000; 1377-1385.
    109. Sachetti E, Vita A, Guarneri L, et al.: The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behavior: preliminary findings. In: Cassano GB, Akiskal HS (Eds): Serotonin-Related Syndromes: Clinical and Therapeutic Links. London, Royal Society of Medicine Services, 1991: pp.47-53.
    110. Salzman C, Schneider L, Lebowitz B: Antidepressant treatment of very old patients. Am J Geriatr Psychiatry 1993; 1: 21-29. Go to original source... Go to PubMed...
    111. Serretti A, Lucca A, Cusin C, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patients. G Ital Psicopatol. 2001; 7: 9-14.
    112. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russel J, Lydiard RB, Crits - Cristoph P, Galop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U. Effectiveness of St. John´s wort in major depression. A randomized controlled trial. JAMA 2001; 285: 1978-1986. Go to original source... Go to PubMed...
    113. Shelton RC. Mood - stabilizing drugs in depression. J Clin Psychiatry 1999; 60(Suppl.2): 37-40.
    114. Shelton RC. Treatment options for refractory depression. J Clin Psychiatry 1999; 60(Suppl.4): 57-61.
    115. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russel J, Lydiard RB, Crits - Cristoph P, Galop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U. Effectiveness of St. John´s wort in major depression. A randomized controlled trial. JAMA 2001; 285: 1978-1986. Go to original source... Go to PubMed...
    116. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buran WH, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134. Go to original source... Go to PubMed...
    117. Simon GE, Heiligenstein JH, Grothaus L, et al.: Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. J Clin Psychiatry 1998; 59: 49-55. Go to original source... Go to PubMed...
    118. Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand 1998; 393 (Suppl.): 95-101. Go to original source... Go to PubMed...
    119. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel JM, Rossi AJ, Soloff PH. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142: 430-436. Go to original source... Go to PubMed...
    120. Švestka J. Antidepresiva. In: Höschl C, Libiger J, Švestka J, eds. Psychiatrie. Praha: Tigis, spol.s.r.o., 2002; 704-717.
    121. Švestka J, Synek O. Účinkuje olanzapin antidepresivně? Dvojitě slepé amitriptylinem kontrolované srovnání. In: 42. Česko-Slovenská psychofarmakologická konference. Sborník abstrakt. Praha: Nakladatelství Galén, 2000; 127.
    122. Teicher M, Glod C, Cole J: Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-210. Go to original source... Go to PubMed...
    123. Thase ME. Long-term treatments of recurrent depressive disorders. J Clin Psychiatry 1992; 56 (Suppl.): 32-44.
    124. Thase ME: Effects of venlafaxine on blood pressure: a metanalysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59: 502-508. Go to original source... Go to PubMed...
    125. Thase ME, Blomgren SL, Birkett MA, et al.: Fluoxetin treatment in patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997; 58: 16-21. Go to original source... Go to PubMed...
    126. Thase ME, Howland RH, Friedman ES. Treating antidepressant nonresponders with augmentation strategies: an overview. J Clin Psychiatry 1998; 59 (Suppl 5): 5-12.
    127. Thase ME, Rush AJ, Howland RH, et al.: Double-blind switch study of imipramine or sertraline of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59: 233-239. Go to original source... Go to PubMed...
    128. Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harvard Review of Psychiatry 1998; 5: 293-306. Go to original source... Go to PubMed...
    129. World Health Organization Mental Health Collaborating Centers: Pharmacotherapy of depressive disorders: a consensus statement. J Affect Disord 1989; 17: 197-198. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.